Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer

Kyong Hwa Park, Ekram Gad, Vivian Goodell, Yushe Dang, Thayer Wild, Doreen Higgins, Patty Fintak, Jennifer Childs, Corazon Dela Rosa, Mary L. Disis

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Breast cancer is immunogenic and well suited to treatment via immunomodulation. The disease is often treated to remission and time to relapse is generally measured in years in many cases. Immune-based therapeutics, such as cancer vaccines, may be able to affect the clinical progression of micrometastatic disease. Immune targets must be identified that have the potential to inhibit tumor growth. Insulin-like growth factor-binding protein-2 (IGFBP-2) has direct effects on breast cancer proliferation via stimulation of critical signaling pathways. We questioned whether IGFBP-2 was an immune target in breast cancer. IGFBP-2-specific IgG antibody immunity was preferentially detected in breast cancer patients compared with controls (P = 0.0008). To evaluate for the presence of T-cell immunity, we identified potential pan-HLA-DR binding epitopes derived from IGFBP-2 and tested the peptides for immunogenicity. The majority of epitopes elicited peptide-specific T cells in both patients and controls and had high sequence homology to bacterial pathogens. IGFBP-2 peptide-specific T cells could respond to naturally processed and presented IGFBP-2 protein, indicating that these peptides were native epitopes of IGFBP-2. Finally, both immunization with IGFBP-2 peptides as well as adoptive transfer of IGFBP-2-competent T cells mediated an antitumor effect in a transgenic mouse model of breast cancer. This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer.

Original languageEnglish
Pages (from-to)8400-8409
Number of pages10
JournalCancer Research
Volume68
Issue number20
DOIs
Publication statusPublished - 2008 Oct 15

Fingerprint

Insulin-Like Growth Factor Binding Protein 2
Immunomodulation
Breast Neoplasms
Peptide T
T-Lymphocytes
Peptides
Epitopes
Immunity
Cancer Vaccines
Critical Pathways
Adoptive Transfer
Neoplasm Antigens
Sequence Homology
Transgenic Mice
Disease Progression
Immunization
Therapeutics
Immunoglobulin G

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. / Park, Kyong Hwa; Gad, Ekram; Goodell, Vivian; Dang, Yushe; Wild, Thayer; Higgins, Doreen; Fintak, Patty; Childs, Jennifer; Dela Rosa, Corazon; Disis, Mary L.

In: Cancer Research, Vol. 68, No. 20, 15.10.2008, p. 8400-8409.

Research output: Contribution to journalArticle

Park, KH, Gad, E, Goodell, V, Dang, Y, Wild, T, Higgins, D, Fintak, P, Childs, J, Dela Rosa, C & Disis, ML 2008, 'Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer', Cancer Research, vol. 68, no. 20, pp. 8400-8409. https://doi.org/10.1158/0008-5472.CAN-07-5891
Park, Kyong Hwa ; Gad, Ekram ; Goodell, Vivian ; Dang, Yushe ; Wild, Thayer ; Higgins, Doreen ; Fintak, Patty ; Childs, Jennifer ; Dela Rosa, Corazon ; Disis, Mary L. / Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. In: Cancer Research. 2008 ; Vol. 68, No. 20. pp. 8400-8409.
@article{16d7404b64c04bbb8dbfcf8846377641,
title = "Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer",
abstract = "Breast cancer is immunogenic and well suited to treatment via immunomodulation. The disease is often treated to remission and time to relapse is generally measured in years in many cases. Immune-based therapeutics, such as cancer vaccines, may be able to affect the clinical progression of micrometastatic disease. Immune targets must be identified that have the potential to inhibit tumor growth. Insulin-like growth factor-binding protein-2 (IGFBP-2) has direct effects on breast cancer proliferation via stimulation of critical signaling pathways. We questioned whether IGFBP-2 was an immune target in breast cancer. IGFBP-2-specific IgG antibody immunity was preferentially detected in breast cancer patients compared with controls (P = 0.0008). To evaluate for the presence of T-cell immunity, we identified potential pan-HLA-DR binding epitopes derived from IGFBP-2 and tested the peptides for immunogenicity. The majority of epitopes elicited peptide-specific T cells in both patients and controls and had high sequence homology to bacterial pathogens. IGFBP-2 peptide-specific T cells could respond to naturally processed and presented IGFBP-2 protein, indicating that these peptides were native epitopes of IGFBP-2. Finally, both immunization with IGFBP-2 peptides as well as adoptive transfer of IGFBP-2-competent T cells mediated an antitumor effect in a transgenic mouse model of breast cancer. This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer.",
author = "Park, {Kyong Hwa} and Ekram Gad and Vivian Goodell and Yushe Dang and Thayer Wild and Doreen Higgins and Patty Fintak and Jennifer Childs and {Dela Rosa}, Corazon and Disis, {Mary L.}",
year = "2008",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-07-5891",
language = "English",
volume = "68",
pages = "8400--8409",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer

AU - Park, Kyong Hwa

AU - Gad, Ekram

AU - Goodell, Vivian

AU - Dang, Yushe

AU - Wild, Thayer

AU - Higgins, Doreen

AU - Fintak, Patty

AU - Childs, Jennifer

AU - Dela Rosa, Corazon

AU - Disis, Mary L.

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Breast cancer is immunogenic and well suited to treatment via immunomodulation. The disease is often treated to remission and time to relapse is generally measured in years in many cases. Immune-based therapeutics, such as cancer vaccines, may be able to affect the clinical progression of micrometastatic disease. Immune targets must be identified that have the potential to inhibit tumor growth. Insulin-like growth factor-binding protein-2 (IGFBP-2) has direct effects on breast cancer proliferation via stimulation of critical signaling pathways. We questioned whether IGFBP-2 was an immune target in breast cancer. IGFBP-2-specific IgG antibody immunity was preferentially detected in breast cancer patients compared with controls (P = 0.0008). To evaluate for the presence of T-cell immunity, we identified potential pan-HLA-DR binding epitopes derived from IGFBP-2 and tested the peptides for immunogenicity. The majority of epitopes elicited peptide-specific T cells in both patients and controls and had high sequence homology to bacterial pathogens. IGFBP-2 peptide-specific T cells could respond to naturally processed and presented IGFBP-2 protein, indicating that these peptides were native epitopes of IGFBP-2. Finally, both immunization with IGFBP-2 peptides as well as adoptive transfer of IGFBP-2-competent T cells mediated an antitumor effect in a transgenic mouse model of breast cancer. This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer.

AB - Breast cancer is immunogenic and well suited to treatment via immunomodulation. The disease is often treated to remission and time to relapse is generally measured in years in many cases. Immune-based therapeutics, such as cancer vaccines, may be able to affect the clinical progression of micrometastatic disease. Immune targets must be identified that have the potential to inhibit tumor growth. Insulin-like growth factor-binding protein-2 (IGFBP-2) has direct effects on breast cancer proliferation via stimulation of critical signaling pathways. We questioned whether IGFBP-2 was an immune target in breast cancer. IGFBP-2-specific IgG antibody immunity was preferentially detected in breast cancer patients compared with controls (P = 0.0008). To evaluate for the presence of T-cell immunity, we identified potential pan-HLA-DR binding epitopes derived from IGFBP-2 and tested the peptides for immunogenicity. The majority of epitopes elicited peptide-specific T cells in both patients and controls and had high sequence homology to bacterial pathogens. IGFBP-2 peptide-specific T cells could respond to naturally processed and presented IGFBP-2 protein, indicating that these peptides were native epitopes of IGFBP-2. Finally, both immunization with IGFBP-2 peptides as well as adoptive transfer of IGFBP-2-competent T cells mediated an antitumor effect in a transgenic mouse model of breast cancer. This is the first report of IGFBP-2 as a human tumor antigen that may be a functional therapeutic target in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=54249086700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249086700&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5891

DO - 10.1158/0008-5472.CAN-07-5891

M3 - Article

VL - 68

SP - 8400

EP - 8409

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -